CTLA4 and neoplasm: Several potential predictors of anti-PD-1 antibody response with favorable outcomes were investigated, such as CTLA4 promoter hypomethylation, PD-L1 expression, mismatch repair deficiency, tumor mutation burden, tumor-infiltrating immune cell features, and circulating immune cells (6–9).